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The use of bacteriophage lysates in the treatment of staphylococcal infection 
has remained a  controversial subject for many years. One major difficulty in 
th  e  acceptance of such rationale has  been the  failure to demonstrate in ~ivo 
interaction between bacteriophage and infecting bacterial cell. 
The  studies  to  be  described  in  this  communication were  undertaken  to 
ascertain whether  or not Staphylococcus  aureus  80/81  and  bacteriophage  81 
were capable of in vivo interaction and to observe the effects of, and to define 
certain factors which influence this interaction. 
Methods 
M/ce.--Swiss mice of the Huntingdon Farm strain were employed and at time of use 
weighed 14 to 16 gm. They were housed 10 to a cage and fed Purina mouse chow and water 
ad libitum. 
Staphylococci.--The strain of Staphylococcus aureus, phage Type 80/81, employed in these 
studies was originally isolated from a wound infection. It was coagulase-positive, produced 
alpha and beta hemolysins, fermented mannitol, and was resistant to penicillin, streptomycin, 
erythromycin, and tetracycline. Stock suspensions of this bacterium were prepared from 18- 
hour growth on trypticase soy agar (BBL) in Roux bottles. The growth from each bottle was 
harvested in 10 ml broth, placed into ampules, glass sealed, and stored at --20°C. Sufficient 
quantities were prepared to provide material for several experiments, and over a period of 
8 to 12 weeks the viable count showed little change. Infectivity  titrations were correspondingly 
reliable. Infection of 14 to 16 grn mice was accomplished by the intraperitoneal injection of 0.2 
ml containing 1.5 )<  109 viable cells suspended in 5 per cent gastric mucin (Wilson granular 
mucin, type 1701-W). This inoculum was invariably lethal to 100 per cent of the untreated 
mice within a 24 hour period; therefore, the 7 to 10 day observation proved to be more than 
adequate. Certain experiments, however, were observed as long as 14 days for comparative 
purposes. 
Ba~teriopkage.--The staphylococcus bacteriophage 81 employed in these studies was re- 
ceived from the Communicable Disease Center, Chamblee, Georgia. Lysates were prepared 
employing the above described S. aureus 80/81 as the propagating strain, in 1 liter Erlen- 
meyer flasks containing 200 ml 4 per cent peptone (Difco Laboratories, Inc., Detroit).  Each 
flask was seeded with a phage to bacteria ratio of approximately 1: 5. The suspensions were 
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placed on a  reciprocating shaker  at  low speed  and  maintained  at  room temperature.  The 
turbid  suspensions  gradually cleared within 4  to 6 hours and held overnight at 4°C before 
centrifugation at 1230 Rcr for 30 minutes followed by filtration through Seitz EK filters.  Such 
lysates, containing approximately 2 to 4 X  101° PFU/ml (plaque-forming units per ml), were 
placed into ampules, glass sealed, and stored at  --20°C. 
Bacteriophage titrations were performed by the agar layer technique as described by Adams 
(1). All titrations were performed, at least, in duplicate. Circulating phage levels were estab- 
fished by bleeding groups of mice from the tail at certain intervals of time. Blood was collected 
in cold heparinized saline (50 u/ml), and centrifuged at 1230 l~Cr for 10 minutes. Supemates 
were titrated as described. Peritoneal washings were obtained by rinsing the peritoneal cavity 
TABLE I 
The Specific Protective  Activity o/Staphylococcus Bacteriophage  81  on  Staphylococcus aureus 
80/81 Infection in Mice 
Inocula* 
S. aureus 80/81 in 5 per cent mucin 
S. aureus 80/81 in 5 per cent mucin 
S. aureus 80/81 in 5 per cent mucin 
S. aureus 80/81 in 5 per cent mucin 
S. aureus 80/81 in 5 per cent mucin 
5 per cent mucin 
5 per cent mucin 
S. aureus 44A in 5 per cent muein 
S. aureus 44A in 5 per cent muein 
S. aureus 80/81 in TSB§ 
S. aureus 80/81 in TSB 
+  bacteriophage 81 
+  bacteriophage 3b 
+  bacteriophage 81  (inacti- 
vated)~ 
+  4 per cent peptone broth 
+  saline 
+  bacteriophage 81 
-4- bacteriophage 3b 
+  bacteriophage 81 
+  4 per cent peptone broth 
+  bacteriophage 81 
+  4 per cent peptone broth 
No. mice  Survivals 
#er c,e.~ 
248  81 
4O  0 
4O  0 
160  0 
4O  0 
40  100 
4O  100 
4O  0 
4O  0 
30  93 
30  20 
* Viable  bacteria  (1.5  X  109) injected  immediately  before  bacteriophage  (1.5  X  10g 
PFU). All inoculations 0.2 ml, intraperitoneally. 
Z~ 70°C,  1 hour. 
§ Trypticase soy broth. 
with cold sterile saline containing 50 u/ml heparin. The suspension  was centrifuged at  1230 
~cr for 10 minutes. Supernates were titrated as described. 
RESULTS 
Protective  Activity  of Staphylococcus  Bacteriophage  Lysates.--The  ability  of 
staphylococcus  bacteriophage  81  to protect mice was demonstrated  in a  series 
of 15 experiments  involving 248 mice. 
The infecting inoeulum contained in 0.2  ml, was injected into one side of the peritoneum 
and the same number of bacteriophage particles or other substances in 0.2 ml was immediately 
injected into the opposite side of the peritoneum. 
The  results  of  these  experiments  are  summarized  in  Table  I.  Of  the total 
number injected, 201 mice or 81 per cent survived an otherwise lethal infection. P.  F.  BARTELL,  I.  S.  THIND~  T. ORR,  W.  S.  BLAKEMORE  15 
The various controls,--which received heat-inactivated (70°C, 1 hour) staphy- 
lococcus bacteriophage 81,  active but  heterologous staphylococcus bacterio- 
phage 3b,  saline,  or broth,--all failed to demonstrate any protective activity 
against S.  aureus,  Type 80/81. When infection was  initiated with S.  aureus, 
Type 44A active preparations of staphylococcus bacteriophage  81  failed to 
encourage any survivors. 
Thus, it was  concluded that preparations of staphylococcus bacteriophage 
81 were capable of exerting a protective effect in mice infected with Staphylo- 
coccus aureus,  Type 80/81. Moreover, this protective activity appeared to be 
dependent upon the use of active, type-specific bacteriophage. 
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Fro.  1.  Influence of bacteriophage to bacteria ratio on mouse survival. 
Influence  of Bacteriophage:  Bacteria  Ratio  at  the  Site  of Infection.--When 
intraperitoneal infection was initiated with 1.5 ×  109 viable cells it was shown 
that administration of an equal number of bacteriophage particles protected 
81 per cent of the mice. It appeared desirable to determine the effectiveness of 
various quantities of bacteriophage delivered to the site of infection. 
Infection of all mice was accomplished  as described. Various dilutions of bacteriophage  81 
were injected so that the following  ratios of phage-bacteria were tested: 1:1, 1:2, 1:4, 1:6, 
1 : 8, 1:10. At 1:1 both phage and bacteria were 1.5 X l09. Injections of 0.2 ml were made one 
immediately following  the other into opposite sides of the peritoneum. 
The results shown in Fig. I  indicate that maximal protection was  obtained 
at a  ratio of 1:2 with 80 per cent mouse survival. An increased quantity of 
bacteriophage  did  not  appear  to  influence  this  value.  However,  decreased 
quantities of bacteriophage, at the site of infection, resulted in a corresponding 
decrease in the number of survivors. Thus, within a  certain range there ap- 
peared  to be  a  linear relationship  between  the  bacteriophage-bacteria ratio 
and the ability of mice to survive infection. 16  STAPHYLOCOCCUS AUREUS AND BACTERIOPHAGE 
The Effect of Time and Sequence of Administration.--Despite  the fact that 
the  staphylococcal mouse  infection  employed in  these  experiments  was  ex- 
tremely rapid and left much to be desired, it was considered desirable to obtain 
some information relating  to  the  prophylactic and  therapeutic  potentials  of 
the bacteriophage lysate material. 
An inoculum of 1.5 X  109 phage was administered to mice at 3, 6, and 12 hours before; 
and 5, 15, and 30 minutes after infection. At zero time both phage and the infecting inoculum 
were injected intraperitoneally, one immediately after the other. The phage to bacteria ratio 
employed was  1:1. 
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FIG. 2.  The effect of time and sequence of administration on mouse survival. 
It can be seen in Fig.  2,  when both bacteriophage and bacterium were in- 
jected at  zero time,  80 per  cent survival  was  observed.  When bacteriophage 
was administered 3 or 6 hours before infection the percentage survival remained 
Unchanged. However, a sharp decline in the number of survivals was noted by 
the 12th hour when only 7 per cent of the mice survived. On the other hand, 
when  infection  was  established  first  and  administration  of  bacteriophage 
delayed, protective activity was severely diminished. At 5 minutes, 65 per cent 
survival was noted and this fell off to 10 per cent survival if 15 minutes elapsed 
before phage was injected. Mter 30 minutes none of the mice survived. Under 
these  circumstances  it  appeared  that  the  outcome of this  infection was  de- 
termined very early in the infectious process, and bacteriophage administration 
after this time interval could not reverse the process. 
In Vivo Interaction of Bacteriophage and Infecting  Bacterial CelL--While the 
experiments which have been described suggested a certain relationship between 
the  bacteriophage  lysate  material  and  mouse  survival,  it  appeared  obvious P.  ]L  BARTELL,  I.  S.  THIND,  T.  ORR,  W.  S.  BLAKEMORE  I7 
that a  more direct approach was necessary to demonstrate a  positive in  vivo 
interaction between bacteriophage and its host cell, S.  aureus. 
Groups of mice were infected with S.  aureus 80/81. All mice were immediately injected 
with 1.5 X 109 PFU bacteriophage  81 into the opposite side of the peritoneum.  The bacterio- 
phage to bacteria ratio employed  was 1: l. Groups  of 5 mice each were bled from the tail at the 
time intervals indicated, postinjection. 
In Fig. 3 the circulating bacteriophage levels are presented. It can be seen 
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Fzo. 3.  P]asma levels of bacteriophage  81 after admimstration to mice infected with S. 
auras  80/81 and to non-infected  mice. 
5 minutes after inoculation and persisted at approximately the same level for 
6  hours.  However, by  12  hours  circulating levels  of bacteriophage were no 
longer detectable, that is, less than  108 PFU/ml plasma.  On the other hand, 
infected mice which were treated with bacteriophage responded quite differ- 
enfly. The 30 minute bleeding indicated a  circulating bacteriophage level of 
less than 1@ PFU/ml, and at 1 hour the levels attained were still below those 
observed in the non-infected groups. However, by 1~  to 2 hours circulating 
bacteriophage  levels  of  infected  mice  were  significantly  higher  than  those 
observed in non-infected mice, and these levels persisted as long as 4 days. 
It should be pointed out  that  the  infected curve does not represent peak 
values of circulating bacteriophage which may be obtained but  serves simply 
to illustrate the point being made here. 
Thus, in the system described,  we have observed: (a) a delayed appearance 
of bacteriophage, (b)  increased circulating  titers, and (c)  extended duration of 
detectable  levels.  These  observations  suggest  that  staphylophage  81  in  the 18  STAPHYLOCOCCUS AUEEUS AND BACTERIOPHAGE 
presence of a  sensitive  host cell is capable of in ,ivo interaction and subsequent 
propagation. 
It was also observed that the phage-bacterium infectious cycle did not con- 
tinue  to final  eradication  of the  infecting  bacterial  cell.  Repeated isolations 
revealed  cells  which  appeared  to  be unchanged  in  regard  to  the  properties 
tested, which included phage and antibiotic sensitivity, alpha and beta hemo- 
lysins,  coagulase,  and mannitol. 
Specificity  of  the  Interaction  as  Demonstrated  by  Circulating  Levels.--Pro- 
tection  experiments  (Table I)  indicated  that  survival of mice infected with 
S.  aureus 80/81 depended upon the use of active, type-specific  bacteriophage 
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FIG.  4.  Plasma  levels of  staphylococcus  bacteriophage 81  after administration to  mice 
infected with S. aur~us 80/81 and S.  ¢mr~s 44A, and to non-infected mice. 
81  preparations.  It was  of interest  to determine  if and  how  this  might  be 
expressed  by following  circulating  bacteriophage levels. 
Groups of mice were infected with S.  aureus  80/81 or S.  aureus 44A in 5 per cent mucin. 
Control mice received 5 per cent mucin alone. All mice were immediately injected with 1.5 X 
109 PFU bacteriophage 81  into the opposite side of the peritoneum. The bacteriophage to 
bacteria ratio employed was 1 : 1. Groups of 5 mice each were bled from the tail at 30, 60, 120, 
and  180 minutes postinjection. 
In Fig.  4 it can be seen that bacteriophage levels in non-infected mice and 
those bearing the heterologous infection with S. aureus 44A roughly paralleled 
each other. In each case, levels of approximately 105 .~ PFU/ml were observed 
at  30  minutes  which  remained  comparatively  unchanged  through  the  180 
minute observation period. However, mice infected with the sensitive S. aureus 
80/81  responded  quite  differently with  a  delayed  appearance  of circulating 
bacteriophage.  The 30 minute bleeding revealed levels  of less than  103 PFU/ P.  F.  BARTELL~ I.  S.  THIND,  T.  OR.R, W.  S.  BLAKEMORE  19 
ml, after which the circulating levels rose sharply to exceed those observed in 
the other groups. 
Thus, it was quite clear that only in those infected mice which received type- 
specific bacteriophage lysate material was there in vivo interaction as evidenced 
by production of bacteriophage. 
Rdationship  between  Circulating  Bacteriophage  Level  and Mouse Survival.- 
The  foregoing  experiments  indicated  that  bacteriophage  81  lysates  were 
effective in mouse protection and that a  definite in' vivo interaction occurred 
between bacteriophage 81 and its sensitive host cell S. aureus 80/81. 
The  following  experiments  were  executed  to  determine  the  relationship 
between circulating bacteriophage levels and mouse survival. 
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FiG. 5.  Relationship between circulating bacteriophage levels and survival of mice. 
Groups of mice were inoculated intraperitoneaUy  with 1.5 X  109 PFU bacteriophage 81 
and then challenged  with 1.5 X  109 S. aureus 80/81 in 5 per cent mucin, intraperitoneaUy, 
at 0, 3, 6, and 12 hours. Tail bleedings  were made prior to inoculation  of the challenge  dose at 
the time indicated. 
Fig.  5  depicts the relationships which were observed. It may be seen that 
when  circulating  bacteriophage  levels  were  approximately  10  s-5  PFU/ml  a 
correspondingly high degree of protective activity was observed. On the other 
hand,  when  circulating  bacteriophage  levels  fell  to  less  than  108  PFU/ml 
protective activity was poor. 
Activity  of  Intravenously  Administered  Bacteriophage.--The  experiments 
discussed so far have dealt exclusively with bacteriophage preparations inocu- 
lated directly into the site of infection. It was of interest to determine if bac- 
teriophage  was  capable,  after  administration  by  the  intravenous  route,  of 
reaching and acting at the site of intraperitoneal infection. 20  STAPHYLOCOCCUS  AUREUS  AND  BACTERIOPHAGE 
Groups of mice  were injected either intraperitoneally or intravenously (tail vein) with 1.5 X 
109 PFU bacteriophage 81. Control mice received sterile broth. Challenge  with S. aureus 80/81 
in 5 per cent mucin was performed at various time intervals. 
Table  II presents  the  results  of this  experiment.  It  is  evident  that  when 
bacteriophage  was  administered  intravenously  the  number  of  survivals  was 
sharply reduced  (20 per cent) as compared to groups which received bacterio- 
phage intraperitoneally (80 per cent). However, it should be  noted that while 
a  decreased activity was observed it was quite definite, protecting against an 
TABLE  II 
Influence  of intravenous  or  intraperitoneal  administration  of bacteriophage on 
survival of m@e infeaed intraperitoneally 
Bacteriophage administration* 
Intravenous  Intraperitonea] 
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Intravenous  Intraperitoneal 
Survivals  Sur-  Survivals 
Group  vival  Group 
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0/20  0  0/20 
0/20  0  0/20 






* Bacteriophage 81; 1.5 X 109 in 0.2 ml. 
S. aureus 80/81; 1.5 X  10  ~  in S per cent mucin, 0.2 ml intraperitoneally. 
otherwise  100  per cent lethal  infection,  and further,  that termination of pro- 
tective activity occurred within  the  same time interval for both groups. 
It was felt that  this point would  be better demonstrated  if the interaction 
could be detected in peritoneal washings of treated mice. 
Groups of mice were inoculated intravenously (tail vein) with 1.5 X 10  9  PFU bacteriophage 
81 and immediately challenged with S. aurens 80/81 in 5 per cent mucin, intraperitoneally. 
Peritoneal washings were obtained at 30, 60, 90, 120, and 180 minutes postchailenge. 
Fig.  6  illustrates  the  interaction  as  observed in  the peritoneal washings  of 
infected  mice.  Bacteriophage  levels found  in  the  peritoneal  washings  of un- 
infected controls are shown for comparison. Thus, it appears that bacteriophage 
was capable of leaving the circulatory system and interacting with its sensitive 
host cell at the site of infection. 
Extended  Protection  of  Treated  Mice.--Approximately  81  per  cent  of  the 
infected mice which received bacteriophage were immediately protected against 
S.  aureus  (Table I). In addition to promoting survival of mice this treatment 
resulted in increased levels of bacteriophage which persisted in the blood stream 
4 to 5 days, and for somewhat longer periods in peritoneal washings and homog- P. F. BARTELL~ I. S. THIN'D~ T. ORR~ W.  S. BLAKE:MORE  21 
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FIG. 6.  Peritoneal interaction between intravenously administered staphylophage 81 and 
S.  aureus 80/81,  intraperitoneal infection. 
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FIG. 7.  Relationship of bacteriophage levels in blood, peritoneal fluids, spleen of treated 
mice, and survivals on various days of challenge subsequent to treatment. 
enates  of spleen.  It became of interest to determine what effect this treatment 
had  on mice,  especially after bacteriophage declined to non-detectable levels. 
Groups of mice were infected with S. aureus, 80/81 intraperitoneaUy  and treated with 1.5 X 
109 PFU bacteriophage 81. Mice were bled from the tail and challenged on days 1, 3, 5, 7, 9, 
14, and 21 days with 1.5 X  109 S. aureus 80/81 in S per cent much. 22  STAPHYLOCOCCUS  AUREUS  AND  BACTERIOPHAGE 
The results  are illustrated in  Fig.  7.  Bacteriophage levels present  in  peri- 
toneal  washings  and  splenic homogenates of treated mice were obtained  in 
separate experiments. Mice challenged 24 hours after such treatment responded 
with a  somewhat increased resistance to infection (83 per cent). However, on 
the 3rd day only 63 per cent survival was observed, and it was striking that the 
decreased  ability  to  withstand  challenge  coincided with  a  decreasing  avail- 
ability of active bacteriophage. Beginning with the 5th day increased resistance 
to challenge was noted, and at 7 through 21 days 90 per cent of the mice sur- 
vived  the  challenge  inoculum.  (This  curve has  been  reproduced  through  4 
experiments and results have been consistent with particular  attention to the 
decreased per cent survival seen on the 3rd day.) 
DISCUSSION 
Recent hospital experiences with antibiotic resistant strains of Staphylococcus 
aureus have stimulated a  resurgence of interest in the control of this micro- 
organism.  Ironically, those very antibiotics which had performed so reliably 
also tended to reduce interest in the search for additional means of combating 
this disease.  However, the dramatic experience apparently left its mark and 
revitalized effort has already seen the development of newer and more effective 
therapeutic agents.  To some,  the immnnoprophylactic approach,  despite its 
many difficulties, holds the greatest promise for reliable control. Interest has 
also focused on the potential therapeutic and immunoprophy]actic usefulness 
of bacteriophage lysate preparations. This approach lost its appeal due to the 
many conflicting clinical reports, the lack of laboratory evidence to strengthen 
such rationale, and the advent of successful antibiotic therapy. The literature 
concerning itself with  bacteriophage therapy is  voluminous and  for obvious 
reasons we have restricted our comments to staphylococcal bacteriophage. 
Experimentally, Krueger (2), Robinson  (3), Sulkin (4), and others failed to observe 
any beneficial effect when bacteriophage  was administered  to staphylococcus-infected 
animals.  Su|kin concluded  that conditions  conducive  to bacterial lysis could not be 
established in vivo. In support of this were the results of Colvin (5), Gratia and Mut- 
saars  (6), and Applebaum  and MacNeal (7) who reported on the in vitro inhibition 
of bacteriophage  activity by pus,  blood,  serum,  and  other body fluids.  However, 
Colvin's observations  indicated that such inhibition  appeared to be of a variable na- 
ture, being dependent upon the particular specimen, as well as the strain of staphy- 
lococcus or bacteriophage employed. MacNeal, McRae, and Colmers (8) demonstrated 
an  increased  opsonic  effect when optimal quantities  of phage  and  staphylococcus 
were mixed and added to human blood. In vivo, Walker (9) observed a reduced severity 
of staphylococcal  lesions  through  the  use  of bacteriophage  lysates, and  Muir  and 
Blakemore (10) first successfully protected staphylococcal  infected mice.  More re- 
cently, a definite in vivo  interaction has been reported (11). 
Clinical use of bacteriophage lysates received encouraging comment from MacNeal 
and Frisbee  (12, 13) and Larkum (14). Such reports dealing with the use of staphy- 
lococcus bacteriophage,  of their very nature, have been difficult to assess or evaluate P. ~,  BARTELL~  I. S. THIND~  T.  ORE,  W.  S. BLAKE~ORE  23 
(15,  16). Many attempts, made out of sheer desperation,  were doomed to failure. 
Without benefit of in v/vo experimental evidence the acceptance of any rationale ad- 
vocating the use of this material was indeed difficult. While experimentation with the 
laboratory animal does not guarantee extrapolation  to the human being, it does pro- 
vide an accessible and easily managed  /n v/vo system with which one  may study 
mechanism of action. On the basis of existing meager knowledge, it appeared prema- 
ture to cast aside a weapon of such potential in our continuous struggle to control 
pathogenic staphylococci. 
In the present study Staphylococcus aureus 80/81 and bacteriophage 81 were 
shown  to  be  capable  of in  vivo  interaction.  This  was  demonstrated by the 
following series  of  events  which  occurred  immediately after  inoculation  of 
infected  mice  with  bacteriophage:  (a)  non-detectable  bacteriophage  levels 
(period of adsorption) followed by (b)  rapidly increased circulating bacterio- 
phage levels (period of release from infected bacterial cells)  and (c) extended 
duration of detectable bacteriophage. It was also observed that the interaction 
was dependent upon the use of active, type-specific bacteriophage which re- 
suited in 81 per cent survival of mice against an otherwise 100 per cent lethal 
challenge. The bacteriophage to bacteria ratio as well as time and sequence of 
administration were found to be influencing factors. It was also shown that 
mice capable of withstanding lethal challenge carried high levels of circulating 
bacteriophage, whereas those succumbing to intraperitoneal infection had only 
low  levels  of  circulating  bacteriophage.  These  circulating  levels  apparently 
reflected active bacteriophage available at the site of peritoneal infection. Of 
great interest was the demonstration that bacteriophage administered intra- 
venously was capable of reaching and interacting with the infecting bacteria 
at the site of infection, as evidenced by bacteriophage production and mouse 
survival. A consideration of the rapidly fatal infecting system employed and 
the  availability of adequate levels  of bacteriophage  at  the  site of infection 
appear to be likely explanations for the limited survival rates observed in this 
circumstance. 
The exact mechanism by which bacteriophage may protect mice from the 
lethal effects of injected staphylococci is unknown since, in the first place, the 
basic cause of death in untreated mice is still vague. However, it is evident that 
bacteriophage does interfere with some further process required for expression 
of the lethal effect. Infection of cocci by bacteriophage might accomplish this 
by  (a)  altering bacterial metabolism so  that cellular processes  are  diverted 
from their usual metabolic functions and (b) destruction of bacterial cells so as 
to reduce the critical number of cocci below the lethal level. Recently, Smith 
(17) has suggested that elaboration of the lethal effect is closely associated with  ~ 
continued bacterial  multiplication after  inoculation,  and the  basic  cause  of 
death appears to be chemical  but  associated with the coccus rather than its 
products. 
It was evident that a continued reinfection of bacterial host cells by bacterio- 24  STAPHYLOCOCCUS  AUREUS  AND  BACTERIOPHAGE 
phage did not occur. This interruption of the phage-bacterinm infectious cycle 
has not, as yet, been closely studied, however, it did not appear to be due to 
emergence of phage resistant mutants, since repeated isolations  yielded bac- 
terial cells which appeared to be unchanged from the original infecting inoculum 
in those characteristics  tested. 
Infected mice which were treated with bacteriophage  lysates were shown to 
respond  with an altered resistance  to infection.  The results  of several  experi- 
ments suggested  that protective activity at zero time and possibly up to 24 
to 48 hours was due to the availability of sufficient active, type-specific bac- 
teriophage.  Treated mice responded  with a  decreased  resistance  to challenge 
on  the  3rd  day,  a  time which  corresponded  with  the period  of decreasing 
bacteriophage  levels. However,  beginning  with  the  5th  day,  a  protective 
mechanism was apparently operative in the absence of significant bacteriophage 
levels which continued to be effective for at least 21 days. The system at this 
point is evidently very complex and several factors appear to be simultaneously 
operative.  Those  factor(s) which may be responsible  for such high levels of 
protective activity are unknown. However,  one might consider (a) stimulated 
phagocytosis and/or (b)  altered cellular  capacity for destruction of bacteria 
brought about through the production of certain specific or non-specific sub- 
stances. In addition, it would appear reasonable to expect antigenic substances 
present in lysates to be effective in the stimulation of antibody. The possibility 
exists that other substances  may be induced  or formed under in vivo circum- 
stances which may participate in the elaboration of protective activity. It is 
known, for example, that antigenic changes may be initiated in bacterial cells 
through the activity of bacteriophage,  and further, that these changes do not 
require lysogenization of the host cell, but may be brought about by bacterio- 
phage in the vegetative state. Certain salmonella bacteriophages  (18-20) have 
been shown to induce the synthesis of polysaccharide moieties of the 0 antigen, 
and diphtherial bacteriophages  (21) in the synthesis of toxic protein.  However, 
it must be stated that we have no evidence that any of these conversions may 
occur under in vivo conditions. 
Future studies have been  oriented to further elucidate the in vlve  charac- 
teristics  of this interaction. Similar consideration  will be extended to include 
other S. aureus and bacteriophage  strains. 
SUMMARy 
Staphylococcus  bacteriophage  81  is  capable  of  in  *ivo interaction  with 
Staphylococcus  aureus,  Type  80/81.  This  is  immediately made  evident  by 
increased  levels  of bacteriophage  and  concomitant survival of 81  per  cent 
infected mice. The reaction is dependent upon the use of active, type-specific 
bacteriophage.  The maximal protective effect is observed at a bacteriophage  to 
bacteria ratio of 1:2  and decreased  quantities of bacteriophage  result in de- P.  F.  BARTELL,  I.  S.  TIHi~D,  T.  ORR~ W.  S.  BLAKE~M~ORE  25 
creased protection. Time and sequence of administration axe also determining 
factors. It is evident that bacteriophage administered intravenously is capable 
of interaction with the infecting bacterial cell at the site of infection. In dvo 
produced bacteriophage is apparently eliminated or otherwise rendered non- 
detectable fairly rapidly, occurring within a period of 5 to 10 days. However, 
it appears  that host defense mechanisms are  stimulated in  the process  and 
actively play a  protective role against subsequent challenge inocula adminis- 
tered up to 3 weeks later. 
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